Developing innovative new chemical entities that transform the treatment paradigm of psychiatric disease — moving beyond symptom management toward rapid-acting, durable therapies.

Health-system purchasing power plus a Spravato-focused MSO, so independent clinics lower their costs and finally collect on reimbursed treatments — without changing how they run.

Turns rigorous psychological screening for psychedelic therapy into $500–$1,000 per patient in real, reimbursable claims — via standard CPT codes, with any EHR, and no tech integration.

Precision neurofeedback built for the weeks after the dose — turning preparation and integration into a billable, EEG-guided program, so clients keep what the medicine opened.

The first continuity-of-care platform for psychedelic therapy, turning what happens between sessions into signals practitioners can act on. Three in four clients finish what they started.

The AI-native operating system for the end-to-end operations of psychedelic therapy and clinical trials — purpose-built where clinics and research sites still run on generic tools and spreadsheets.

Psychedelics can open the door; we help you walk through it. Education and support for engaging with psychedelics responsibly and turning their potential into lasting change in how you live, relate, and contribute.